Celltrion said Monday that it has begun canceling approximately 2.3 million treasury shares to enhance shareholder value.Following the launch of the unified Celltrion, the company aims to bolster its global competitiveness, maintaining shareholder-friendly policies such as outstanding share repurcha
Huons, a Korean healthcare company listed on Kosdaq, said Monday it has received IND approval from the Ministry of Food and Drug Safety for HUC1-394, a treatment for dry eye disease, to conduct a phase 1 clinical trial. HUC1-394 is a peptide-based eye drop for dry eyes. In 2020, Huons licensed-in th
AstraZeneca Korea said that the Ministry of Food and Drug Safety (MFDS) approved Ultomiris (ingredient: ravulizumab) as an adjunct therapy for adults with antibody-positive acetylcholine receptor (AChR) generalized myasthenia gravis (gMG) on Thursday.Ultomiris had been approved for the treatment of
Celltrion said Friday that its Remicade biosimilar, Remsima SC (infliximab), for the treatment of autoimmune diseases, is showing rapid sales growth in Australia.Launched in Australia in July 2021, Remsima SC generated approximately 8 billion won ($6.1 million) in sales in 2022, followed by cumulati
Korea recorded a trade deficit due to the global economic downturn in 2023, despite achieving the highest export volume in December.Notably, the biotech and healthcare industry, one of the five promising sectors, has experienced a continuous deficit for 16 months since July 2022.Despite an increase
GC Cell said that BioCentriq, its U.S. affiliate focused on cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), successfully raised a total of $29.2 million in a Series A funding.BioCentriq was acquired by GC Cell and Green Cross Holdings in 2022. The company, bas
Dong-A ST said it has signed a licensing agreement with SK biopharmaceuticals for the epilepsy drug cenobamate in 30 countries, including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkey.The deal excludes the U.S. as cenobamate has been commercially available in the U.
The recent regulatory approval of bispecific antibodies Lunsumio (mosunetuzumab) and Columvi (glofitamab) in Korea has opened new treatment options for patients with relapsed lymphoma. Attention is particularly on a possible rivalry between Roche’s Columvi and Novartis’ CAR-T therapy Kymriah (tisage
Korean pharmaceutical and biotech firms are set to participate in the upcoming J.P. Morgan Healthcare Conference, the world's largest healthcare conference known for capturing the interest of institutional investors. The event is scheduled to commence in San Francisco, the U.S., from Jan. 8-11.The c
Dong-A ST said Wednesday that it has launched a combination drug, Sugatree Tab, for type 2 diabetes.Sugatree combines evogliptin 5 mg, the main component of Suganon, a dipeptidyl peptidase 4 (DPP-4) inhibitor, with dapagliflozin 10 mg, sodium-glucose transport protein 2 (SGLT-2) inhibitor, and 1,000
Pfizer's second-generation targeted therapy for chronic myeloid leukemia, Bosulif (bosutinib), has been newly registered with the health insurance program this month.A patient group welcomed the news and called for expanding its reimbursement to treat children.Last Dec. 22, the Ministry of Health an
Medytox, a Korean botulinum toxin (BTX) maker, said it has established a U.S. subsidiary Luvantas to advance into the global market with MT10109L, its non-animal-derived liquid BTX formulation.The company had submitted a biologics license application (BLA) for MT10109L to the FDA in late December. T
MedPacto, a Korean immunotherapy developer, said Wednesday that the U.S. FDA has approved a phase 2b/3 investigational new drug (IND) plan for the combination of its immunotherapy, vactosertib, and MSD’s Keytruda (pembrolizumab), in patients with metastatic colorectal cancer.For phase 2b/3 study, Me
In their New Year's messages on Tuesday, major Korean pharmaceutical companies praised their employees for their hard work in overcoming crises, such as Covid-19 and the economic downturn, and expressed their determination to become global pharmaceutical companies by developing innovative new drugs.
Kolon Life Science said Wednesday that its patent on alleviating or treating pain for neuropathic pain gene therapy, KLS-2031, and a patent on a recombinant vaccinia virus for anti-cancer gene therapy, KLS-3021, won registration in India.KLS-2031 features a recombinant adeno-associated virus (rAAV)
Helixmith said its gene therapy Engensis, also known as VM202-DPN, failed to meet the primary endpoint in a phase 3 clinical trial for treating diabetic peripheral neuropathy (DPN) conducted in the U.S.The phase 3 DPN trial was divided into two studies, 3-2 and 3-2b, where the primary endpoint invol
NKMAX, a Korean natural killer (NK) cell-based immunotherapy company, said Tuesday that its U.S. affiliate, NKGen Biotech, has completed dosing the first patient in its phase 1/2a Alzheimer's disease clinical trial of SNK01, an NK cell therapy for Alzheimer’s disease, in the U.S.In October last year
The Celltrion Group on Tuesday announced the divestiture of primary care business rights in the Asia-Pacific acquired from Takeda Pharmaceutical in 2020, excluding domestic ethical drugs (ETC).In 2020, Celltrion acquired the business rights in the Asia-Pacific region for 18 brands of Takeda Pharmace
When couples consider initial gifts to celebrate the arrival of a new baby, they commonly think of umbilical cord stamps, or hand and foot sculptures. However, capturing a photo of the fundus, the clear inner part of the child's eye, could be more crucial because detecting congenital eye diseases in
BL Pharmtech, a Kosdaq-listed health functional food company, said Friday that it has completed the sale of its subsidiary, BL Healthcare, to Kwangdong Pharmaceutical.BL Healthcare specializes in health functional foods and is engaged in bio-new material research and functional cosmetics business.On
